INT35164

From wiki-pain
Revision as of 17:12, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1980
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 96
Total Number 103
Disease Relevance 76.30
Pain Relevance 9.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
eosinophil 6
mast cells 6
nasal 3
plasma 2
skin 2
IGHE (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 817 100.00 Very High Very High Very High
cytokine 809 100.00 Very High Very High Very High
Angina 20 100.00 Very High Very High Very High
Codeine 10 100.00 Very High Very High Very High
metalloproteinase 8 100.00 Very High Very High Very High
agonist 160 99.98 Very High Very High Very High
Morphine 11 99.64 Very High Very High Very High
corticosteroid 281 99.46 Very High Very High Very High
tolerance 58 99.06 Very High Very High Very High
cva 15 98.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 852 100.00 Very High Very High Very High
Hyperplasia 40 100.00 Very High Very High Very High
Cv General 3 Under Development 23 100.00 Very High Very High Very High
Disorders Of Creatine Metabolism 5 100.00 Very High Very High Very High
Repression 5 100.00 Very High Very High Very High
Strongyloidiasis 184 99.70 Very High Very High Very High
General Immunology 135 99.70 Very High Very High Very High
Anaphylaxis 168 99.40 Very High Very High Very High
Cerebral Malaria 59 99.40 Very High Very High Very High
Hypersensitivity 935 99.36 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
IgE inhibition did not predict clinical relevant cross-reactivity.
Negative_regulation (inhibition) of IgE
1) Confidence 0.58 Published 2007 Journal Anesthesiology Section Body Doc Link 17667569 Disease Relevance 0 Pain Relevance 0
The decrease in total IgE levels in the CM group was associated with a higher intensity of mast cell degranulation induced in vitro by P. falciparum-specific IgE.
Negative_regulation (decrease) of IgE in mast cell associated with cerebral malaria
2) Confidence 0.57 Published 2007 Journal Malar J Section Body Doc Link PMC1781948 Disease Relevance 0.58 Pain Relevance 0.16
Seven of 14 adult patients with chronic pancreatitis had measurable IgE in feces, and the concentrations were up to ten times the upper limit of IgE found in healthy individuals.
Negative_regulation (limit) of IgE in feces associated with chronic pancreatitis
3) Confidence 0.57 Published 1986 Journal Int. Arch. Allergy Appl. Immunol. Section Abstract Doc Link 3949413 Disease Relevance 0.66 Pain Relevance 0.15
In addition, 84 different household chemicals were tested, by IgE antibody inhibition, for SUX and MOR.
Negative_regulation (inhibition) of IgE
4) Confidence 0.57 Published 2005 Journal Acta Anaesthesiol Scand Section Body Doc Link 15777289 Disease Relevance 0 Pain Relevance 0
The authors have documented a similar predisposition in AIC patients with deficiencies in IgE [22].
Negative_regulation (deficiencies) of IgE associated with general immunology
5) Confidence 0.52 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2837605 Disease Relevance 1.01 Pain Relevance 0
Doses ranging from 0.0005 to 0.14 mg/kg subcutaneously or 0.05 to 1.0 mg/kg intravenously decrease free serum IgE levels in plasma in a dose-dependent fashion in both adults and children (Barnes 2000; Fahy 2000).
Negative_regulation (decrease) of IgE in plasma
6) Confidence 0.51 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899803 Disease Relevance 0.31 Pain Relevance 0.04
A number of studies have demonstrated the beneficial effects of reducing the serum levels of IgE, first by the model of allergen challenge (Boulet et al 1997; Fahy et al 1997) and then by clinical trials in adults and children (Milgrom et al 1999; Solèr et al 2001; Busse et al 2001; Buhl et al 2002; Finn et al 2003; Corren et al 2003; Bousquet et al 2005; Holgate et al 2005; Humbert et al 2005) with severe asthma.
Negative_regulation (reducing) of IgE associated with asthma
7) Confidence 0.44 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727776 Disease Relevance 0.63 Pain Relevance 0.21
In a first placebo-controlled trial on subjects with ragweed-induced rhinitis, only patients with a significant decrease in IgE levels, and thus requiring higher doses of omalizumab – up to 375 mg every 2 weeks – showed a clinical efficacy (Casale et al 1997).
Negative_regulation (decrease) of IgE associated with rhinitis
8) Confidence 0.44 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727776 Disease Relevance 0.56 Pain Relevance 0.14
With such doses, a significant reduction of free IgE occurs as early as 24–48 hours from the first administration by subcutaneous route (Jardieu et al 1999; Lin et al 2004), while a significant inhibition of clinical symptoms – by a specific allergen challenge – occurs after 1 week (Lin et al 2004).
Negative_regulation (reduction) of IgE
9) Confidence 0.44 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727776 Disease Relevance 0.88 Pain Relevance 0
Comparison of intravenous administration of omalizumab with placebo in patients with mild asthma not receiving inhaled corticosteroids resulted in a significant decrease in serum free IgE levels from baseline concentrations (P<0.00001 and P<0.001 in two separate studies) (Boulet et al. 1997; Fahy et al. 1997).
Negative_regulation (decrease) of IgE associated with asthma and corticosteroid
10) Confidence 0.43 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899803 Disease Relevance 0.10 Pain Relevance 0.05
The inhibition experiments revealed that the alcuronium-IgE reaction could be prevented or diminished by structures containing a substituted ammonium ion.
Negative_regulation (diminished) of IgE
11) Confidence 0.43 Published 1983 Journal Mol. Immunol. Section Abstract Doc Link 6656781 Disease Relevance 0.14 Pain Relevance 0.10
Cross-reactivity between drugs was assessed by IgE inhibition and skin tests.
Negative_regulation (inhibition) of IgE in skin
12) Confidence 0.43 Published 2007 Journal Anesthesiology Section Body Doc Link 17667569 Disease Relevance 0 Pain Relevance 0
Of note, the t(11;14) translocation is considered a hallmark of IgE, IgM, and nonsecretory MM, all rare subtypes of MM [15].
Negative_regulation (hallmark) of IgE associated with multiple myeloma
13) Confidence 0.42 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC2944146 Disease Relevance 1.96 Pain Relevance 0
Prevalence of IgE antibodies to morphine.
Negative_regulation (Prevalence) of IgE associated with codeine and morphine
14) Confidence 0.41 Published 2005 Journal Acta Anaesthesiol Scand Section Title Doc Link 15777289 Disease Relevance 0.19 Pain Relevance 0.39
BACKGROUND: Treatment with omalizumab has been shown to reduce serum free IgE concentrations and to have beneficial effects on allergic airway disease.
Negative_regulation (reduce) of IgE associated with hypersensitivity and disease
15) Confidence 0.40 Published 2004 Journal Ann. Allergy Asthma Immunol. Section Abstract Doc Link 15478383 Disease Relevance 0.20 Pain Relevance 0
Omalizumab decreases free serum IgE levels in a dose-dependent manner, reduces IgE receptor density on effector cells, and significantly improves airway inflammation parameters.
Negative_regulation (decreases) of IgE associated with inflammation
16) Confidence 0.40 Published 2004 Journal Treat Respir Med Section Abstract Doc Link 15219177 Disease Relevance 0.45 Pain Relevance 0.13
Omalizumab decreases free serum IgE levels in a dose-dependent manner, reduces IgE receptor density on effector cells, and significantly improves airway inflammation parameters.
Negative_regulation (decreases) of IgE associated with inflammation
17) Confidence 0.40 Published 2004 Journal BioDrugs Section Abstract Doc Link 15571425 Disease Relevance 0.45 Pain Relevance 0.13
CONCLUSIONS: Omalizumab treatment markedly reduced serum free IgE and the clinical response to nasal allergen challenge.
Negative_regulation (reduced) of IgE in nasal
18) Confidence 0.40 Published 2004 Journal Ann. Allergy Asthma Immunol. Section Body Doc Link 15478383 Disease Relevance 0.11 Pain Relevance 0
RESULTS: During treatment, serum free IgE concentrations were decreased by 97% to 99%, and the nasal response to allergen challenge was significantly reduced on days 80 and 164.
Negative_regulation (decreased) of IgE in nasal
19) Confidence 0.40 Published 2004 Journal Ann. Allergy Asthma Immunol. Section Body Doc Link 15478383 Disease Relevance 0.14 Pain Relevance 0
IgE levels decreased significantly in patients treated with the higher dose of MP (125 mg), while there was not much of a decrease in the IgE levels in patients treated with either HC or with a lower dose of MP (60 mg).[17] In another study, 14 patients with acute bronchial asthma were treated with HC (100 mg IV q 6-hourly), MP (20 mg IV q 6-hourly) or dexamethasone (3.75 mg IV q 6-hourly).
Negative_regulation (decrease) of IgE associated with asthma and dexamethasone
20) Confidence 0.40 Published 2010 Journal Journal of Emergencies, Trauma and Shock Section Body Doc Link PMC2938487 Disease Relevance 0.83 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox